Given these practical constraints, clinicians, formulary decision-makers, and payers should use a patient-centered approach, balancing efficacy, costs, patient preferences, and safety considerations when selecting obesity pharmacotherapy
Comparing Semaglutide, Tirzepatide, and Dual-Compound Options for Younger Users Semaglutide targets GLP-1 receptors only, making it suitable for patients seeking single-pathway activation or those sensitive to dual-mechanism agents
Compounded semaglutide contains the same active ingredient as Ozempic, Wegovy, and Rybelsus, but it hasn't been FDA-approved
7 GLP1 is not currently covered under Part D for weight loss, and such excess growth of GLP utilization over diabetic use growth may reflect off-label prescribing, expanded use following new indications or broader prescribing patterns across eligible populations